A phase III trial of LP-003 in allergic rhinitis
Latest Information Update: 27 Feb 2024
At a glance
- Drugs LP 003 Longbio Pharma (Primary)
- Indications Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors LongBio Pharma
Most Recent Events
- 27 Feb 2024 New trial record
- 25 Feb 2024 According to a Longbio Pharma media release, the company expects to start the phase III study of allergic rhinitis at 2024 Q1/2 around March 2024, and will get the topline result for LP-003 Phase III study by the end of 2024 and prepare for BLA in 2025H1.